What is HC Wainwright’s Forecast for OVID FY2026 Earnings?

Ovid Therapeutics Inc. (NASDAQ:OVID) – Research analysts at HC Wainwright issued their FY2026 EPS estimates for Ovid Therapeutics in a research report issued to clients and investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.60) for the year. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share.

Several other brokerages also recently commented on OVID. BTIG Research dropped their target price on shares of Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Monday. Oppenheimer raised shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price objective on the stock in a research report on Wednesday, January 29th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $3.00 target price (down from $4.00) on shares of Ovid Therapeutics in a research note on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $3.03.

Ovid Therapeutics Trading Down 5.4 %

NASDAQ:OVID opened at $0.41 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.66 and a quick ratio of 5.66. The business’s 50-day simple moving average is $0.59 and its 200-day simple moving average is $0.92. Ovid Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $3.45. The stock has a market capitalization of $28.93 million, a PE ratio of -0.87 and a beta of 0.29.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.19 million.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in OVID. XTX Topco Ltd lifted its position in Ovid Therapeutics by 46.2% during the 3rd quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock worth $45,000 after buying an additional 12,076 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Ovid Therapeutics by 1.1% in the third quarter. Geode Capital Management LLC now owns 1,317,330 shares of the company’s stock valued at $1,555,000 after acquiring an additional 14,816 shares during the last quarter. Rhumbline Advisers raised its holdings in Ovid Therapeutics by 22.3% during the fourth quarter. Rhumbline Advisers now owns 84,078 shares of the company’s stock worth $79,000 after acquiring an additional 15,355 shares in the last quarter. SG Americas Securities LLC boosted its position in Ovid Therapeutics by 83.9% during the fourth quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock valued at $35,000 after purchasing an additional 17,172 shares during the last quarter. Finally, Kennedy Capital Management LLC boosted its position in Ovid Therapeutics by 1.1% during the fourth quarter. Kennedy Capital Management LLC now owns 1,545,387 shares of the company’s stock valued at $1,443,000 after purchasing an additional 17,402 shares during the last quarter. Institutional investors and hedge funds own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.